Beta Drugs Ltd

{
  "main_header": {
    "sid": 1002857,
    "name": "Beta Drugs Ltd",
    "stock_name": "Beta Drugs Ltd",
    "full_name": "Beta Drugs Ltd",
    "name_url": "stocks-analysis/beta-drugs",
    "exchange": 1,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,771.20",
    "chg": 295.2,
    "chgp": "20.0%",
    "dir": 1,
    "prev_price": "1,476.00",
    "mcapval": "1,561.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "BETA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE351Y01019",
    "curr_date": "Jun 12, 03:56 PM",
    "curr_time": "16:53 PM",
    "last_traded_at": "Jun 12, 03:56 PM IST",
    "bse_nse_vol": 180651,
    "exc_status": "Active",
    "traded_date": "Jun 12, 2026",
    "traded_date_str": "2026 06 12",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/beta-drugs-1002857-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Beta Drugs Ltd Locks at Upper Circuit With 19.4% Gain — Buyers Queue, Sellers Absent",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/beta-drugs-ltd-surges-194-to-hit-upper-circuit-amid-robust-buying-pressure-4049099",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BetaDrugsLtd_stocks_hitting_upper_circuit_4049099.png",
        "date": "2026-06-12 12:00:14",
        "description": "At Rs 1,760, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Beta Drugs Ltd locked at its upper circuit of 19.24% on 12 Jun 2026, with buyers queuing and no sellers willing to part with shares."
      },
      {
        "title": "Beta Drugs Ltd Valuation Shifts to Very Expensive Amidst Strong Price Gains",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/beta-drugs-ltd-valuation-shifts-to-very-expensive-amidst-strong-price-gains-4043204",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BetaDrugsLtd_valuationdot_4043204.png",
        "date": "2026-06-10 08:01:31",
        "description": "Beta Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a marked shift in its valuation parameters, moving from an expensive to a very expensive rating. This change, coupled with a recent 6.49% intraday price surge, invites a closer examination of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical trends and peer benchmarks."
      },
      {
        "title": "Beta Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/beta-drugs-ltd-is-rated-sell-4041027",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/BetaDrugsLtd_mojoScore_4041027.png",
        "date": "2026-06-09 10:10:03",
        "description": "Beta Drugs Ltd is rated Sell by MarketsMOJO. This rating was last updated on 14 May 2026, reflecting a comprehensive assessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 09 June 2026, providing investors with the latest perspective on the company’s position in the market."
      },
      {
        "title": "Beta Drugs Ltd is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/beta-drugs-ltd-is-rated-sell-by-marketsmojo-4016617",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BetaDrugsLtd_mojoScore_4016617.png",
        "date": "2026-05-27 10:10:04",
        "description": "Beta Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Beta Drugs Ltd Faces Technical Momentum Shift Amid Declining Prices",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/beta-drugs-ltd-faces-technical-momentum-shift-amid-declining-prices-3996139",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BetaDrugsLtd_technicaldot_3996139.png",
        "date": "2026-05-18 08:02:58",
        "description": "Beta Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, signalling a transition from a sideways trend to a mildly bearish stance. This change is underscored by a combination of mixed technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively suggest caution for investors amid recent price declines."
      },
      {
        "title": "Beta Drugs Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/beta-drugs-ltd-is-rated-sell-3994089",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BetaDrugsLtd_mojoScore_3994089.png",
        "date": "2026-05-16 10:10:03",
        "description": "Beta Drugs Ltd is rated 'Sell' by MarketsMOJO. This rating was assigned on 14 May 2026, reflecting a comprehensive evaluation of the stock’s prospects. However, all fundamentals, returns, and financial metrics discussed here are current as of 16 May 2026, providing investors with the latest insight into the company’s position."
      },
      {
        "title": "Beta Drugs Q4 FY26: Margin Compression Clouds Otherwise Steady Quarter",
        "link": "https://www.marketsmojo.com/news/result-analysis/beta-drugs-q4-fy26-margin-compression-clouds-otherwise-steady-quarter-3993394",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/BetaDrugs_quaterlyResult_3993394.png",
        "date": "2026-05-15 17:19:30",
        "description": "Beta Drugs Ltd., a Himachal Pradesh-based pharmaceutical manufacturer, reported a marginal increase in consolidated net profit for Q4 FY26, posting ₹9.05 crores compared to ₹9.03 crores in Q4 FY25, representing a modest year-on-year growth of 1.12%. The ₹1,343 crore market capitalisation company saw its stock plunge 9.38% following the results announcement, reflecting investor disappointment with deteriorating profitability margins despite revenue growth."
      }
    ],
    "total": 69,
    "sid": "1002857",
    "stock_news_url": "https://www.marketsmojo.com/news/beta-drugs-1002857"
  },
  "announcements": [
    {
      "details": "Beta Drugs Limited has informed the Exchange regarding 'International Plant Approvals'.",
      "source": "NSE",
      "caption": "Beta Drugs Limited - Updates",
      "datetime": "15-Nov-2019"
    },
    {
      "details": "Beta Drugs Limitedgs Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.",
      "source": "NSE",
      "caption": "Beta Drugs Limited - Reply to Clarification- Financial results",
      "datetime": "14-Nov-2019"
    },
    {
      "details": "Beta Drugs Limiteded for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.",
      "source": "NSE",
      "caption": "Beta Drugs Limited - Clarification - Financial Results",
      "datetime": "08-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Beta Drugs Ltd has announced <strong>1:20</strong> bonus issue, ex-date: 26 Mar 25",
          "dt": "2025-03-26",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Beta Drugs Ltd Locks at Upper Circuit With 19.4% Gain — Buyers Queue, Sellers Absent

2026-06-12 12:00:14

At Rs 1,760, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Beta Drugs Ltd locked at its upper circuit of 19.24% on 12 Jun 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

Beta Drugs Ltd Valuation Shifts to Very Expensive Amidst Strong Price Gains

2026-06-10 08:01:31

Beta Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a marked shift in its valuation parameters, moving from an expensive to a very expensive rating. This change, coupled with a recent 6.49% intraday price surge, invites a closer examination of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical trends and peer benchmarks.

Read full news article

Beta Drugs Ltd is Rated Sell

2026-06-09 10:10:03

Beta Drugs Ltd is rated Sell by MarketsMOJO. This rating was last updated on 14 May 2026, reflecting a comprehensive assessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 09 June 2026, providing investors with the latest perspective on the company’s position in the market.

Read full news article

Beta Drugs Ltd is Rated Sell by MarketsMOJO

2026-05-27 10:10:04

Beta Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Beta Drugs Ltd Faces Technical Momentum Shift Amid Declining Prices

2026-05-18 08:02:58

Beta Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, signalling a transition from a sideways trend to a mildly bearish stance. This change is underscored by a combination of mixed technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, which collectively suggest caution for investors amid recent price declines.

Read full news article

Beta Drugs Ltd is Rated Sell

2026-05-16 10:10:03

Beta Drugs Ltd is rated 'Sell' by MarketsMOJO. This rating was assigned on 14 May 2026, reflecting a comprehensive evaluation of the stock’s prospects. However, all fundamentals, returns, and financial metrics discussed here are current as of 16 May 2026, providing investors with the latest insight into the company’s position.

Read full news article

Beta Drugs Q4 FY26: Margin Compression Clouds Otherwise Steady Quarter

2026-05-15 17:19:30

Beta Drugs Ltd., a Himachal Pradesh-based pharmaceutical manufacturer, reported a marginal increase in consolidated net profit for Q4 FY26, posting ₹9.05 crores compared to ₹9.03 crores in Q4 FY25, representing a modest year-on-year growth of 1.12%. The ₹1,343 crore market capitalisation company saw its stock plunge 9.38% following the results announcement, reflecting investor disappointment with deteriorating profitability margins despite revenue growth.

Read full news article

View All News